I reported previously (Apr 2018) when Israel’s Endospan received the CE mark for its Horizon stent graft system to treat Abdominal Aortic Aneurysm. It now also has received the CE mark for its Nexus Stent Graft System to treat Aortic Arch Disease.

https://www.fdanews.com/articles/190639-endospan-earns-ce-mark-for-aortic-arch-repair-system